Shares of OPKO Health (NASDAQ:OPK) jumped 13.9% in September, according to data from S&P Global Market Intelligence, after it began its coronavirus vaccine testing program in New York City schools and again following phase 2 testing starting on a COVID-19 treatment.
OPKO’s stock plunged over 35% in August after Abbott Labs (NYSE:ABT) announced it would begin offering a cheap, quick COVID-19 test at the end of the month. OPKO’s BioReference Labs offers a slightly slower test that takes 24 to 72 hours to see results.
The lab, though, began its testing for all principals, teachers, and staff of the New York City school system on Sept. 2, helping to lift shares. Then, in the middle of the month, it announced its COVID-19 therapy Rayaldee would enter clinical-trials testing.
One of the markers seen with COVID-19 patients is a vitamin D deficiency, and